Astellas: Data show fidaxomicin's efficacy, cost savings

Astellas Pharma Inc. (Tokyo:4503) said a pooled analysis showed that patients receiving fidaxomicin to treat Clostridium difficile infection (CDI) had reduced mortality, recurrence rates and healthcare costs compared with standard-of-care (SOC) vancomycin and metronidazole.

The real-world study data came from five U.K. hospitals that began giving patients fidaxomicin as first-line treatment for CDI in 2012. Data were presented Wednesday at the Federation of Infection Societies (FIS) conference. ...